Prevention and treatment of graft-carried carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation: a report of 13 cases

Lan Zhu, Zhi-qiang Wang, K. Ma, H. Feng, G. Zhao, J. Jia, Xinqiang Wang, Zheng-bin Lin, Gang Chen
{"title":"Prevention and treatment of graft-carried carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation: a report of 13 cases","authors":"Lan Zhu, Zhi-qiang Wang, K. Ma, H. Feng, G. Zhao, J. Jia, Xinqiang Wang, Zheng-bin Lin, Gang Chen","doi":"10.3760/CMA.J.ISSN.0254-1785.2019.06.003","DOIUrl":null,"url":null,"abstract":"Objective \nTo evaluate the efficacy of tigecycline plus prolonged high-dose meropenem infusion in the prevention and treatment of early carbapenem-resistant Klebsiella pneumoniae (CRKP) infection after renal transplantation. \n \n \nMethods \nFrom January 2016 to December 2018, clinical data were retrospectively analyzed for 13 renal transplant recipients with graft-carried CRKP. The relevant clinical data included treatments and outcomes of grafts and recipients.KPC-2 gene was the only resistance gene detectable in all isolates of CRKP. Among 13 CRKP positive recipients, there were positive cultures of graft preservation solution, recipient blood & urine (n=1), positive cultures of graft preservation solution & urine (n=1), positive cultures of graft preservation solutions & peri-graft drainage (n=3), continuous positive cultures of peri-graft drainage more than twice (n=3) and positive culture of graft preservation solution (n=5). All patients received tigecycline plus prolonged high-dose meropenem infusion-based antibiotics. \n \n \nResults \nFive patients with CRKP positive in preservation solution were successfully prevented from infection after a treatment period of (12.4±2.1)days. Among another 8 cases, additional topical medications (n=3) and surgical debridement (n=1) were used. It took a median time of 16 (7~60) days until a negative culture and the total antibiotic treatment course was 20 (10~93) days. The average hospitalization duration was (50±35) days. During a median follow-up period of 25 (6~28) months, there was no onset of renal arterial rupture, graft nephrectomy or death. The survival rate was 100% for recipients and 92.3% for grafts. \n \n \nConclusions \nFor post-transplant infections due to graft-carried KPC-2 producing CRKP, rapid diagnostics and tigecycline plus prolonged high-dose meropenem infusion may optimize clinical outcomes by decreasing the rate of graft nephrectomy and the recipient mortality. \n \n \nKey words: \nKidney transplantation; Donor; Klebsiella pneumoniae; Infection; Prognosis","PeriodicalId":9885,"journal":{"name":"Chineae Journal of Organ Transplantation","volume":"36 1","pages":"328-333"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chineae Journal of Organ Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.0254-1785.2019.06.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To evaluate the efficacy of tigecycline plus prolonged high-dose meropenem infusion in the prevention and treatment of early carbapenem-resistant Klebsiella pneumoniae (CRKP) infection after renal transplantation. Methods From January 2016 to December 2018, clinical data were retrospectively analyzed for 13 renal transplant recipients with graft-carried CRKP. The relevant clinical data included treatments and outcomes of grafts and recipients.KPC-2 gene was the only resistance gene detectable in all isolates of CRKP. Among 13 CRKP positive recipients, there were positive cultures of graft preservation solution, recipient blood & urine (n=1), positive cultures of graft preservation solution & urine (n=1), positive cultures of graft preservation solutions & peri-graft drainage (n=3), continuous positive cultures of peri-graft drainage more than twice (n=3) and positive culture of graft preservation solution (n=5). All patients received tigecycline plus prolonged high-dose meropenem infusion-based antibiotics. Results Five patients with CRKP positive in preservation solution were successfully prevented from infection after a treatment period of (12.4±2.1)days. Among another 8 cases, additional topical medications (n=3) and surgical debridement (n=1) were used. It took a median time of 16 (7~60) days until a negative culture and the total antibiotic treatment course was 20 (10~93) days. The average hospitalization duration was (50±35) days. During a median follow-up period of 25 (6~28) months, there was no onset of renal arterial rupture, graft nephrectomy or death. The survival rate was 100% for recipients and 92.3% for grafts. Conclusions For post-transplant infections due to graft-carried KPC-2 producing CRKP, rapid diagnostics and tigecycline plus prolonged high-dose meropenem infusion may optimize clinical outcomes by decreasing the rate of graft nephrectomy and the recipient mortality. Key words: Kidney transplantation; Donor; Klebsiella pneumoniae; Infection; Prognosis
肾移植术后移植物携带耐碳青霉烯肺炎克雷伯菌感染的防治(附13例报告
目的评价替加环素联合大剂量美罗培南长期输注预防和治疗肾移植术后早期耐碳青霉烯肺炎克雷伯菌(CRKP)感染的疗效。方法回顾性分析2016年1月至2018年12月13例肾移植患者移植体携带CRKP的临床资料。相关临床资料包括移植物和受者的治疗和结果。KPC-2基因是所有分离株中唯一检测到的耐药基因。13例CRKP阳性受体中,移植物保存液、受体血液和尿液阳性培养(n=1),移植物保存液和尿液阳性培养(n=1),移植物保存液和移植物周围引流阳性培养(n=3),移植物周围引流连续阳性培养2次以上(n=3),移植物保存液阳性培养(n=5)。所有患者均接受替加环素加长时间大剂量美罗培南输注抗生素治疗。结果5例保存液中CRKP阳性的患者经(12.4±2.1)d的治疗后均成功避免感染。另外8例患者采用局部药物治疗(n=3)和手术清创(n=1)。中位时间为16 (7~60)d至阴性培养,抗生素总疗程为20 (10~93)d。平均住院时间为(50±35)d。中位随访25(6~28)个月,无肾动脉破裂、移植物肾切除术或死亡发生。受者存活率为100%,移植物存活率为92.3%。结论对于移植物携带的KPC-2产生CRKP引起的移植后感染,快速诊断和替加环素加长时间大剂量美罗培南输注可通过降低移植物肾切除术率和受体死亡率来优化临床结果。关键词:肾移植;捐赠;肺炎克雷伯菌;感染;预后
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信